Geron Corporation $GERN Stake Raised by Renaissance Technologies LLC

Key Points

• Renaissance Technologies increased its Geron stake by 144.1% in the first quarter, holding 1.8 million shares worth approximately $2.7 million. Institutional investors collectively own 73.71% of the company.
• Analyst sentiment remains mixed, with Geron carrying a consensus “Hold” rating and an average price target of $4.00; Weiss Ratings downgraded the stock to “sell (e+).”
• Geron reported $57.48 million in quarterly revenue, above analyst expectations, but its $0.02-per-share loss missed estimates and the company remains unprofitable. Shares opened at $1.48, within a 52-week range of $1.04 to $2.01.

Renaissance Technologies LLC raised its holdings in Geron Corporation (NASDAQ:GERN - Free Report) by 144.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,799,521 shares of the biopharmaceutical company's stock after acquiring an additional 1,062,355 shares during the quarter. Renaissance Technologies LLC owned 0.28% of Geron worth $2,681,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Soleus Capital Management L.P. raised its holdings in shares of Geron by 572.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 16,140,000 shares of the biopharmaceutical company's stock worth $22,757,000 after purchasing an additional 13,740,000 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in Geron during the third quarter worth approximately $12,364,000. Millennium Management LLC boosted its holdings in Geron by 97.8% during the third quarter. Millennium Management LLC now owns 11,367,989 shares of the biopharmaceutical company's stock worth $15,574,000 after buying an additional 5,620,635 shares in the last quarter. Eversept Partners LP grew its position in Geron by 40.2% in the fourth quarter. Eversept Partners LP now owns 17,659,983 shares of the biopharmaceutical company's stock worth $23,311,000 after buying an additional 5,060,981 shares during the last quarter. Finally, RA Capital Management L.P. grew its position in Geron by 5.6% in the fourth quarter. RA Capital Management L.P. now owns 63,771,366 shares of the biopharmaceutical company's stock worth $84,178,000 after buying an additional 3,392,000 shares during the last quarter. Institutional investors own 73.71% of the company's stock.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Geron from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $4.00.

Geron Stock Performance

GERN stock opened at $1.48 on Monday. The firm has a 50 day simple moving average of $1.34 and a 200 day simple moving average of $1.47. Geron Corporation has a 52 week low of $1.04 and a 52 week high of $2.01. The stock has a market cap of $950.86 million, a P/E ratio of -13.45 and a beta of 0.61. The company has a debt-to-equity ratio of 0.55, a quick ratio of 5.16 and a current ratio of 6.91.

Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. The company had revenue of $57.48 million during the quarter, compared to analyst estimates of $55.30 million. Research analysts anticipate that Geron Corporation will post -0.04 earnings per share for the current fiscal year.

Key Geron News

Here are the key news stories impacting Geron this week:

• Positive Sentiment: Geron reported record second-quarter revenue of $57.48 million, exceeding the $55.30 million analyst consensus, with growth attributed to demand for Rytelo. The revenue beat supports the commercial potential of the company’s lead product. Geron adds a record 16% as Rytelo drives Q2 revenue beat
• Positive Sentiment: Traders purchased a large volume of Geron call options, signaling that some market participants are positioning for potential upside in GERN. However, options activity does not guarantee a sustained move in the stock. Stock Traders Buy Large Volume of Geron Call Options
• Neutral Sentiment: Analyst opinions on Geron remain mixed, indicating uncertainty about the company’s earnings trajectory and the pace at which Rytelo can translate into profitability. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Geron reported a second-quarter loss of $0.02 per share, missing the $0.01-per-share loss analysts expected. Its negative net margin and continued losses highlight that the company has not yet achieved profitability. Geron: Q2 Earnings Snapshot
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026 through 2030, including estimates of a $0.05 loss for 2026, $0.02 EPS for 2027, $0.12 for 2028, $0.32 for 2029 and $0.55 for 2030. The revisions suggest weaker near- and long-term earnings expectations, likely contributing to selling pressure. HC Wainwright Geron EPS Estimates

Geron Profile

Geron Corporation NASDAQ: GERN is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company's research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source